<DOC>
	<DOC>NCT02570035</DOC>
	<brief_summary>This purpose of this study is to investigate the effects of mirabegron on the cardiovascular system in patients with overactive bladder with current or a history of cardiovascular disease.</brief_summary>
	<brief_title>Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>having coexisting cardiovascular disease or a history of cardiovascular diseases having electrocardiogram record conducted within seven days before the start of the mirabegron treatment (including the first day of administration) having serious cardiovascular disease having significant long QT (QTc &gt; 500 msec)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Mirabegron</keyword>
	<keyword>Overactive Bladder</keyword>
	<keyword>Cardiovascular Disease</keyword>
</DOC>